A Pilot Trial to Study the Availability and Effect of Post-OP IV Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Cells Retrieved From the Peritoneal Cavity
Ovarian cancer is the sixth most common cancer and the seventh most common cause of cancer
deaths in women across the globe. The majority of women, nearly 70%, will present with
advanced stage disease that heralds a poor prognosis.
Despite aggressive treatment that still favors initial debulking surgery followed by a
platinum and taxane based chemotherapy regimen, most patients relapse after achieving a
complete clinical response.
Our group has shown that the ketorolac can inhibit gene activity which inhibits cell
proliferation and migration.Ketorolac will be used in this study with the goal of producing
specific inhibition of cell adhesion and migration in ovarian cancer cells retrieved within
the peritoneal cavity after cytoreductive surgery.
Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label
Measure levels of Ketorolac in peritoneal cavity
To determine the concentration of measurable levels of R and S- Ketorolac (and the percent racemic mixture) in the peritoneal cavity after intravenous (IV) administration in the post-operative patient after cytoreductive surgery.
Carolyn Muller, MD
UNM Cancer Center
United States: Food and Drug Administration
|University of New Mexico Cancer Center||Albuquerque, New Mexico 87131-5636|